ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

EDEN Eden Research Plc

4.05
-0.075 (-1.82%)
09 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Eden Research Plc LSE:EDEN London Ordinary Share GB0001646941 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.075 -1.82% 4.05 4.00 4.10 4.125 3.675 4.13 1,278,141 14:19:34
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Biological Pds,ex Diagnstics 1.83M -2.24M -0.0042 -11.90 26.67M
Eden Research Plc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker EDEN. The last closing price for Eden Research was 4.13p. Over the last year, Eden Research shares have traded in a share price range of 3.20p to 12.00p.

Eden Research currently has 533,352,523 shares in issue. The market capitalisation of Eden Research is £26.67 million. Eden Research has a price to earnings ratio (PE ratio) of -11.90.

Eden Research Share Discussion Threads

Showing 12776 to 12796 of 18000 messages
Chat Pages: Latest  516  515  514  513  512  511  510  509  508  507  506  505  Older
DateSubjectAuthorDiscuss
20/6/2022
14:26
Fake Neutral. You cannot back up your accusations. Anyone who reads this will now be fully aware that you are a FRAUD.
ravenna23
20/6/2022
14:25
FFS,

it looks like ravenna has caught the same condition his dopey (Filtered) tag team partner is suffering from.

weyweyumfozo
20/6/2022
14:20
Hundreds of times a year? Please list all of my posts since June 20th 2021 to validate your accusation. If not go back to your pit.
ravenna23
20/6/2022
14:15
Pump.....and dump
ravenna23
20/6/2022
14:12
Wow, 8000 pounds of buys. Board must be filling their boots. NOT.
ravenna23
20/6/2022
13:56
Fraud Neutral loves a Soho peep show. Trouble is he is running out of coins. Sad
ravenna23
20/6/2022
13:51
Hi Fraud Neutral, who else do you like to WATCH
ravenna23
20/6/2022
13:47
Fraud Neutral has, never invested a pound in Eden. I have. He/she just likes to watch.
ravenna23
20/6/2022
13:32
Don't believe Tricky or Fraud, they don't invest, they just like to watch. Hmm.
ravenna23
20/6/2022
13:27
If you think institutional investors will intervene, wake up. Besides it is not their money they are losing, it is your supposed safe pension funds.
ravenna23
20/6/2022
13:22
Don't believe me, invest your hard earned cash into Eden at 1p. Abracadabra it will disappear ?
ravenna23
20/6/2022
13:21
The current market shakedown is designed to take out Zombies like Eden. Anyone who cannot see that the board have raped shareholders is in denial. Ten days until half year end, six weeks until market update regarding lack of sales. The stated position in year end accounts will have worsened. Institutional investors will no longer pour good money after bad. The company will fail within a year
ravenna23
19/6/2022
16:38
U.S. EPA ORDERED TO REASSESS GLYPHOSATE'S IMPACT ON HEALTH, ENVIRONMENT
supersonico
18/6/2022
07:18
Court Says EPA Shirked Duties on Glyphosate
POSTED BY ZEN HONEYCUTT ON JUNE 17, 2022

A historic win today!

From the Center for Food Safety:

SAN FRANCISCO — Today, in a historic victory for farm workers and the environment, the U.S. Court of Appeals for the Ninth Circuit sided with the Center for Food Safety (CFS) and its represented farmworker and conservation clients by overturning the Environmental Protection Agency's (EPA) decision that the toxic pesticide glyphosate is safe for humans and imperiled wildlife. Glyphosate is the active ingredient in Monsanto-Bayer's flagship Roundup weed killer, the most widely used pesticide in the world.

supersonico
17/6/2022
16:55
>>> ARCHIVED

BARRELMAN 17 Jun '22 - 11:22 - 12295
> How refreshing to see an intelligent post on this site,I don’t suppose it will last long when certain people see it.

This bluey ID of the ramping gang of sockpuppets will hopefully prove their undoing when we motivate the Police, instructed by the FSA, to get ADVFN to identify the source of the payment for this fraudulent account "BARRELMAN".

I hope Sambo or is it Rastus who will deflorate it when we are successful.... it will be like Eden.... know what I mean? Bars and all.

;)

neutralpov
17/6/2022
16:50
ravenna23 17 Jun '22 - 16:10 - 12333
> A wise person would follow the example of Amati, a previous major shareholder, and continually sell down their holding.
> Perhaps Tricky and Fraud have been buying?

Yep, they managed £20 between them.

THE FORGER NeutraIPOV 17 Jun '22 - 16:18 - 12334
> Perhaps they will.

You stupid tw*t, ravenna's reference to "FRAUD" is to YOU.

lol

neutralpov
17/6/2022
16:10
A wise person would follow the example of Amati, a previous major shareholder, and continually sell down their holding.Perhaps Tricky and Fraud have been buying?
ravenna23
17/6/2022
15:49
You should be Neutral Numpty
ravenna23
17/6/2022
15:48
Cenkos are Edens PAID broker, their job is to convince ordinary people that Eden is an Opportunity Caveat Emptor.
ravenna23
17/6/2022
15:45
OpportunityOpportunity Opportunity Reality equals ZERO
ravenna23
17/6/2022
15:40
Cenkos Report 2022

Page 6, available for anyone to read. Link on Eden's website.

A £197 million per annum future opportunity based on proven and developed/developing products.


Eden Research market opportunities

We analyse the potential for Eden Research’s currently marketed and pipeline opportunities in more detail in this report, providing an overview of the market potential below. In aggregate, we believe Eden Research is targeting significant market opportunities, which could transform the company in the near- to mid-term.

 Mevalone – Grapes in the Southern EU zone. Assuming a market share of 10%, we estimate this opportunity could be worth c£10m to Eden Research.

 Mevalone – Apples/grapes in the Central EU zone. Assuming a market share of 10%, we estimate this opportunity could also be worth c£10m to Eden Research.

 Cedroz – We estimate the potential revenues for Cedroz to treat nematodes in the markets covered by the Eastman Chemicals could be c£24m assuming a 10% market share.

 Insecticide – Combining the US and European markets, we estimate the insecticide opportunity could be worth c£58m assuming a 10% market share.

 Seed treatment – Eden Research’s seed treatment development with Corteva has the potential to generate c€40m of sales to the company per year.

 Sustaine opportunities – Eden Research estimate that the two lead development projects for Sustaine could generate a combined c£60m per year revenue opportunity.

investingisatrickygame
Chat Pages: Latest  516  515  514  513  512  511  510  509  508  507  506  505  Older

Your Recent History

Delayed Upgrade Clock